Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India

• Published in: Asian Pacific journal of cancer prevention : APJCP 2015, Vol.16 (12), p.4959-4964
• Main Authors: Doval, Dinesh Chandra, Sharma, Anila, Sinha, Rupal, Kumar, Kapil, Dewan, Ajay Kumar, Chaturvedi, Harit, Batra, Ullas, Talwar, Vineet, Gupta, Sunil Kumar, Singh, Shailendra, Bhole, Vidula, Mehta, Anurag
• Format: Article
• Language: Korean
• ISSN: 1513-7368; 2476-762X

Background: To assess the immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2) neu receptor in breast cancer and their associations with various clinicopathological characteristics. Materials and Methods: This is a retrospective analysis of women who presented with primary, unilateral breast cancer in the Department of Medical Oncology at Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India during the period from January 2008 to December 2011. Data were retrieved from the medical records of the hospital including both early and locally advanced cancer cases. ER, PgR and HER2neu expression in these patients was assessed and triple negative patients were identified. Associations of triple negative and non-triple negative groups with clinicopathological characteristics were also evaluated. Results: A total of 1,284 women (mean age 52.1 years, 41.9% premenopausal) were included in the analysis. Hormone receptor positivity (ER and/or PgR) was seen in 63.4% patients, while 23.8% of tumors were triple negative. Only 23.0% were HER2 positive. Around 10.0% of tumors were both ER and HER2 positive. ER and PgR positivity was significantly associated with negative HER2 status (p-value